Thursday, February 23, 2017 7:26:31 PM
2 patients were partial responders and 1 patient had a complete response by the 9th month of treatment. The 1 partial responder is only at the 6 month stage so may become a complete responder with further treatments. The 1 partial responder at 12 months seems to be responding slower than the other responders. So this could mean that patients that do respond to the combo therapy are slowly becoming complete responders by the one year mark.
The 2 partial responders are continuing on so the next data readout will be critical.
It is amazing that Oncosec is getting a response in patients that have 100% failure to pd-1 monotherapy.
This is big and the market doesn't care today. So we need more patient data going forward which I believe we will get later on in this trial which will be enough positive data to get the green light for the registration trial.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM